Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome
To access this article, please choose from the options below
This work was supported by U01 HL068285 (Lacro); U01 HL068270 (Wruck, Mahony, Colan, Klein), U01 HL068269 (Li), U01 HL068292 (Minich), U01 HL068290 (Printz, Devereux, Roman), U01 HL068288 (Bradley), U01 HL068281 (Saul), and U01 HL068279 (Paridon, Pyeritz) from the National Heart, Lung, and Blood Institute (Bethesda, MD), the Howard Hughes Medical Institute (Baltimore, MD) (Dietz); the National Marfan Foundation (Port Washington, NY) (Dietz); and the Smilow Center for Marfan Syndrome Research (Baltimore, MD) (Dietz).
PII: S0002-8703(07)00528-5
doi:10.1016/j.ahj.2007.06.024
© 2007 Mosby, Inc. All rights reserved.
